Advancing light scattering assays for AAV products

March 19, 15:00 GMT/ 16:00 CET/ 11:00 EDT/ 08:00 PDT

AAV-based gene therapy products are heterogeneous, composed of empty, partial, and full monomer capsid species as well as capsid aggregates and fragments. Join our exclusive webinar where Dr Margaret Butko, Director of CMC Assay Development, Adverum and Dr. Prithwijit Sarkar, Sr. System Account Manager, Waters|Wyatt Technology, will present two methods: GMP-compliant DLS (dynamic light scattering) which is used for monitoring capsid aggregation, including generation of a capsid aggregation standard, and the FFF-MALS (field-flow fractionation coupled with multi-angle light scattering) method, used for quantifying the relative abundance of capsid aggregates.

Explore these two methods, with the addition of quantification platform SEC-MALS (size exclusion chromatography coupled with multi-angle light scattering), to quantify the relative abundance of both capsid aggregates and full capsids. Find out how you can elevate your AAV-based gene therapy research with these tools and ensure the delivery of consistent products to patients.

Key learning objectives:

• Explore DLS applications to monitor capsid aggregation in a GMP setting
• Discover FFF-MALS applications to quantify the relative abundance of capsid aggregates
• Investigate SEC-MALS applications to quantify the relative abundance of full capsids

Who should attend?

• CMC teams supporting AAV-based therapies
• Scientists involved in AAV characterization, analytical method development, process development, and quality control
• Lab managers that need to select and support an optimal set of AAV characterization methods

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.